# OnCo record paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020" ;
  schema:name "Anti-PD-1 checkpoint inhibitor therapy in acral melanoma: a multicentre study of 193 Japanese patients"@en ;
  schema:description "In the largest series of acral melanoma treated with anti-PD-1 antibodies, only about 17 percent responded, and melanomas of the nail apparatus responded least, showing that acral disease benefits less from immunotherapy than ordinary skin melanoma."@en ;
  schema:url <https://onco.cc/key-papers/paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.annonc.2020.05.031>, <https://pubmed.ncbi.nlm.nih.gov/32522691/> ;
  schema:sameAs <https://doi.org/10.1016/j.annonc.2020.05.031> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Nakamura Y, Namikawa K, Yoshino K, et al." ;
  onco:cancers <https://onco.cc/cancers/acral-melanoma/> ;
  onco:journals <https://onco.cc/journals/annals-of-oncology/> .